CHANDRABARTHOLOMEUSZCHANDRA BARTHOLOMEUSZ8757BARTHOLOMEUSZ, CHANDRAAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1515 Holcombe BlvdHouston77030-4009TXAuthorship 1765445Authorship 1781176Authorship 1807127Authorship 1877364Authorship 1881727Authorship 195851216294215Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NTCancer gene therapyReduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther. 2006 May; 13(5):451-9.Cancer Gene Ther2006-05-01T00:00:002006Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells.17575145Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NTCancer researchAcquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007 Jun 15; 67(12):5779-88.Cancer Res2007-06-15T00:00:002007Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.21652059Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NTGynecologic oncologyNovel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep; 122(3):641-7.Gynecol Oncol2011-06-08T00:00:002011Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.21712485Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NTThe oncologistPrognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011; 16(7):956-65.Oncologist2011-06-28T00:00:002011Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.23543364Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NTMolecular cancer therapeuticsBisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther. 2013 Jun; 12(6):1099-111.Mol Cancer Ther2013-03-29T00:00:002013Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.Breast Medical OncologyExperimental Radiation OncologyExperimental TherapeuticsGynecological Oncology & Reproductive MedicineLeukemiaMolecular & Cellular OncologySystems BiologyMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessor1.988530.00285797229research areas5.669740.011652133coauthor of56.15089.4625760similar to1147selected publicationsVENKATA LOKESHBATTULAVENKATA LOKESH BATTULA9435BATTULA, VENKATA LOKESHAssistant ProfessorNAOTO TUENONAOTO T UENO8465UENO, NAOTO TProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorGEOFFREYBARTHOLOMEUSZGEOFFREY BARTHOLOMEUSZ8749BARTHOLOMEUSZ, GEOFFREYAssociate ProfessorSAVITRIKRISHNAMURTHYSAVITRI KRISHNAMURTHY8777KRISHNAMURTHY, SAVITRIProfessorBISRAT GODEFAYDEBEBBISRAT GODEFAY DEBEB9486DEBEB, BISRAT GODEFAYAssistant ProfessorANIL KSOODANIL K SOOD9048SOOD, ANIL KProfessorAuthorship 2184582Authorship 2260591Authorship 2276496Authorship 2301111Authorship 2322531Authorship 232813310656456Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MCClinical cancer research : an official journal of the American Association for Cancer ResearchE1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.Clin Cancer Res2000-01-01T00:00:002000E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.19010903Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NTCancer researchPEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 2008 Nov 15; 68(22):9302-10.Cancer Res2008-11-15T00:00:002008PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival.20455002Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu KJournal of neuro-oncologyExpression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol. 2010 Dec; 100(3):449-57.J Neurooncol2010-05-09T00:00:002010Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.22144664Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NTMolecular cancer therapeuticsMEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb; 11(2):360-9.Mol Cancer Ther2011-12-05T00:00:002011MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.22584435Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortob?gyi GNThe oncologistHigh ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist. 2012; 17(6):766-74.Oncologist2012-05-14T00:00:002012High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients.23073759Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NTBreast cancer research and treatmentRole of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):331-45.Breast Cancer Res Treat2012-10-17T00:00:002012Role of epidermal growth factor receptor in breast cancer.Authorship 24262113Authorship 2483801Authorship 2483861Authorship 2491993Authorship 2499372Authorship 253535111454891Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MCJournal of clinical oncology : official journal of the American Society of Clinical OncologyCationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.J Clin Oncol2001-07-15T00:00:002001Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.16166319Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NTCancer researchBcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13.Cancer Res2005-09-15T00:00:002005Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.16170361Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NTOncogeneAntitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. 2006 Jan 05; 25(1):79-90.Oncogene2006-01-05T00:00:002006Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15.17218636Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NTMolecular cancer therapeuticsAdenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther. 2007 Jan; 6(1):227-35.Mol Cancer Ther2007-01-11T00:00:002007Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.17612393Sugimoto T, Bartholomeusz C, Tari AM, Ueno NTBreast cancer research : BCRAdenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res. 2007; 9(4):R41.Breast Cancer Res2007-01-01T00:00:002007Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.17671085Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NTMolecular cancer therapeuticsSensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007 Aug; 6(8):2168-77.Mol Cancer Ther2007-08-01T00:00:002007Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.20215547Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NTClinical cancer research : an official journal of the American Association for Cancer ResearchPEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010 Mar 15; 16(6):1802-11.Clin Cancer Res2010-03-09T00:00:002010PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase.Authorship 270298122239433Bartholomeusz C, Gonzalez-Angulo AMExpert opinion on therapeutic targetsTargeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan; 16(1):121-30.Expert Opin Ther Targets2012-01-12T00:00:002012Targeting the PI3K signaling pathway in cancer therapy.Authorship 2784515Authorship 2852071Authorship 2895639Authorship 2903072Authorship 29147611Authorship 29244111Authorship 2981261Authorship 29925410Authorship 3023536Authorship 303490421850211Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NTJournal of CancerGemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. J Cancer. 2011; 2:435-42.J Cancer2011-08-07T00:00:002011Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.24703838Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AKCell reportsAntagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.Cell Rep2014-04-03T00:00:002014Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.24916181Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NTBreast cancer research and treatmentA class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014 Jul; 146(2):259-72.Breast Cancer Res Treat2014-06-12T00:00:002014A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.25304382Xie X, Tang H, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie XCancer lettersDevelopment of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):374-381.Cancer Lett2014-10-07T00:00:002014Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.25435280Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, Esteva FJMolecular oncologyHER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2015 Mar; 9(3):586-600.Mol Oncol2014-11-11T00:00:002014HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.25971596Boulbes DR, Chauhan GB, Jin Q, Bartholomeusz C, Esteva FJBreast cancer research and treatmentCD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat. 2015 Jun; 151(3):501-13.Breast Cancer Res Treat2015-05-14T00:00:002015CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.26384399Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NTMolecular cancer therapeuticsMEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Mol Cancer Ther. 2015 Dec; 14(12):2773-81.Mol Cancer Ther2015-09-17T00:00:002015MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.26443806Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NTMolecular cancer therapeuticsAntitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther. 2015 Dec; 14(12):2687-99.Mol Cancer Ther2015-10-06T00:00:002015Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.26640591Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao AJournal of CancerComprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer. 2015; 6(12):1306-19.J Cancer2015-10-28T00:00:002015Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.74Professor10Assistant Professor14Associate Professor18644997Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NTMolecular cancer therapeuticsActivity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):1846-50.Mol Cancer Ther2008-07-01T00:00:002008Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.Authorship 843376Authorship 853887Authorship 858924Authorship 867839Journal of CancerGemcitabine overcomes erlotinib resistance in EGFR overexpressing cancer cells through downregulation of Akt. Journal of Cancer. 2:435-442.Gemcitabine overcomes erlotinib resistance in EGFR overexpressing cancer cells through downregulation of AktMolecular Cancer TherapeuticsAntitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases. Molecular Cancer Therapeutics. 14:2687-2699.Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinasesMolecular Cancer TherapeuticsMEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Molecular Cancer Therapeutics. 14:2773-2781.MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft modelJournal of CancerComprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. Journal of Cancer. 6:1306-1319.Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast CancerD019950Chemicals & Drugs1912810.875417Mitogen-Activated Protein Kinase 1D010750Chemicals & Drugs51711550.647269PhosphoproteinsD047908Chemicals & Drugs59812650.633723Intracellular Signaling Peptides and ProteinsD051017Chemicals & Drugs3156180.780279Apoptosis Regulatory ProteinsAuthorship 9180169Authorship 91858012Authorship 9262864Authorship 92683314Authorship 927084628351607Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KNBioorganic & medicinal chemistryDiscovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. Bioorg Med Chem. 2017 05 01; 25(9):2609-2616.Bioorg Med Chem2017-03-10T00:00:002017Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.28415808Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff MOncotargetIKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget. 2017 Jun 06; 8(23):36936-36949.Oncotarget2017-06-06T00:00:002017IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells.28978083Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NTOncotargetEGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget. 2017 Sep 15; 8(40):67904-67917.Oncotarget2017-07-04T00:00:002017EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.29057053Jose J, Tavares CDJ, Ebelt ND, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KNACS medicinal chemistry lettersSerotonin Analogues as Inhibitors of Breast Cancer Cell Growth. ACS Med Chem Lett. 2017 Oct 12; 8(10):1072-1076.ACS Med Chem Lett2017-09-14T00:00:002017Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.28764577Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz CExpert opinion on therapeutic targetsMELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opin Ther Targets. 2017 09; 21(9):849-859.Expert Opin Ther Targets2017-08-16T00:00:002017MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.PathologyAuthorship 940760630826934Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NTBreast cancer research and treatmentAnti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351.Breast Cancer Res Treat2019-03-02T00:00:002019Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.Authorship 945331630982934Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NTBreast cancer research and treatmentCorrection to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jul; 176(1):251.Breast Cancer Res Treat2019-07-01T00:00:002019Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.Authorship 9468351031058487Sammons RM, Perry NA, Li Y, Cho EJ, Piserchio A, Zamora-Olivares DP, Ghose R, Kaoud TS, Debevec G, Bartholomeusz C, Gurevich VV, Iverson TM, Giulianotti M, Houghten RA, Dalby KNACS chemical biologyA Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. ACS Chem Biol. 2019 06 21; 14(6):1183-1194.ACS Chem Biol2019-05-13T00:00:002019A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.D064726Disorders31811970.485715Triple Negative Breast NeoplasmsAuthorship 978562532102425Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J, McLaughlin KM, Wass MN, Michaelis M, Kalayda GVCellsNon-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells. 2020 02 24; 9(2).Cells2020-02-24T00:00:002020Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin.Authorship 9900421732444778Gagliardi M, Pitner MK, Park J, Xie X, Saso H, Larson RA, Sammons RM, Chen H, Wei C, Masuda H, Chauhan G, Kondo K, Tripathy D, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz CScientific reportsDifferential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep. 2020 05 22; 10(1):8537.Sci Rep2020-05-22T00:00:002020Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.Authorship 1006947833323457Xie X, Lee J, Liu H, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, Ueno NTMolecular cancer therapeuticsBirinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Mol Cancer Ther. 2021 02; 20(2):296-306.Mol Cancer Ther2020-12-15T00:00:002020Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.Authorship 10235631834241740Park J, Tacam MJ, Chauhan G, Cohen EN, Gagliardi M, Iles LR, Ueno NT, Battula VL, Sohn YK, Wang X, Kim HS, Krishnamurthy S, Fowlkes NW, Green MM, Bartholomeusz GA, Tripathy D, Reuben JM, Bartholomeusz CBreast cancer research and treatmentNonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Res Treat. 2021 Sep; 189(2):333-345.Breast Cancer Res Treat2021-07-09T00:00:002021Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression.Authorship 10730822437377604Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz CCancer research communicationsMaternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2023 06; 3(6):1078-1092.Cancer Res Commun2023-06-20T00:00:002023Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer.Authorship 10882142538282551Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Bertucci F, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz CCancer research communicationsCorrection: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2024 Jan 29; 4(1):236.Cancer Res Commun2024-01-29T00:00:002024Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor